Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 100 mg in type 2 diabetes patients on lipid-lowering therapy
2005-002316-24Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary dyslipidaemia and type 2 diabetes mellitus (T2DM) comparing TAK-475 100 mg with Placebo (2 arms). Primary endpoint: Fasting direct plasma LDL cholesterol. Started Jul 2005; status: completed.
02
Drugs
lapaquistat
03
Conditions
primary dyslipidaemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-002316-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002316-24.